Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression

Oncotarget

Volumn 6, Issue 29, 2015, Pages 27613-27627

  Barger, Carter J ^a   Zhang, Wa ^a   Hillman, Joanna ^b   Stablewski, Aimee B ^b   Higgins, Michael J ^b   Vanderhyden, Barbara C ^c   Odunsi, Kunle ^b   Karpf, Adam R ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

E2F1; Epithelial ovarian cancer; FOXM1; p53; Rb

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; VIRUS LARGE T ANTIGEN; E2F1 PROTEIN, HUMAN; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTOR; FOXM1 PROTEIN, HUMAN; PROTEIN P53; RETINOBLASTOMA PROTEIN; TP53 PROTEIN, HUMAN; VIRUS T ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER MODEL; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE PROGRESSION; CELL IMMORTALIZATION; CONTROLLED STUDY; FEMALE; FOXM1 GENE; GENE EXPRESSION REGULATION; GENE LOCUS; GENE OVEREXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; OVARIAN SURFACE EPITHELIAL CELL; OVARY CARCINOMA; OVARY CELL; PROTEIN EXPRESSION; RB1 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; CELL CYCLE; CELL PROLIFERATION; CYSTADENOCARCINOMA; GENE EXPRESSION PROFILING; GENETICS; HUMAN GENOME; METABOLISM; MUTATION; NEOPLASM; OVARY TUMOR; TRANSGENIC ANIMAL; TUMOR CELL LINE;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; E2F1 TRANSCRIPTION FACTOR; FEMALE; FORKHEAD BOX PROTEIN M1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HUMANS; MICE; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84944458703     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4546     Document Type: Article

References (67)

1. Cannistra S.A. Cancer of the ovary. N Engl J Med. 2004; 351:2519-29.
2. Vaughan S, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011; 11:719-25.
3. Bast R.C Jr, Hennessy B, Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009; 9:415-28.
4. Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474:609-15.
5. Kuo K.T, et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009; 69:4036-42.
6. Ciriello G, et al. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45:1127-1133.
7. Etemadmoghadam D, et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A. 2013; 110:19489-94.
8. Karst A.M, et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 2014; 74:1141-52.
9. Patch A.M, et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015; 521:489-94.
10. Myatt S.S, Lam E.W. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007; 7:847-59.
11. Chen X, et al. The forkhead transcription factor FOXM1 controls cell cycle-dependent gene expression through an atypical chromatin binding mechanism. Mol Cell Biol. 2013; 33:227-36.
12. Halasi M, Gartel A.L. FOX(M1) news--it is cancer. Mol Cancer Ther. 2013; 12:245-54.
13. Pandit B, Halasi M, Gartel A.L. p53 negatively regulates expression of FoxM1. Cell Cycle. 2009; 8:3425-7.
14. Barsotti A.M, Prives C. Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene. 2009; 28:4295-305.
15. McGovern U.B, et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther. 2009; 8:582-91.
16. Levanon K, et al. FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. Oncogene. 2014; 33:4424-32.
17. Blanco-Bose W.E, et al. C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology. 2008; 48:1302-11.
18. Mencalha A.L, et al. Forkhead box M1 (FoxM1) gene is a new STAT3 transcriptional factor target and is essential for proliferation, survival and DNA repair of K562 cell line. PLoS One. 2012; 7:e48160.
19. Teh M.T, et al. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res. 2002; 62:4773-80.
20. Kong X, et al. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. Cancer Res. 2013; 73:3987-96.
21. Xia L.M, et al. Transcriptional up-regulation of FoxM1 in response to hypoxia is mediated by HIF-1. J Cell Biochem. 2009; 106:247-56.
22. Millour J, et al. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. Mol Cancer Ther. 2011; 10:1046-58.
23. Yu J, et al. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res. 2011; 17:1924-34.
24. Korver W, Roose J, Clevers H. The winged-helix transcription factor Trident is expressed in cycling cells. Nucleic Acids Res. 1997; 25:1715-9.
25. Korver W, et al. The winged-helix transcription factor Trident is expressed in actively dividing lymphocytes. Immunobiology. 1997; 198:157-61.
26. Park H.J, et al. Anaphase-promoting complex/cyclosome-CDH1-mediated proteolysis of the forkhead box M1 transcription factor is critical for regulated entry into S phase. Mol Cell Biol. 2008; 28:5162-71.
27. Anders L, et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell. 2011; 20:620-34.
28. Wang I.C, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. Mol Cell Biol. 2005; 25:10875-94.
29. Wang I.C, et al. FoxM1 regulates transcription of JNK1 to promote the G1/S transition and tumor cell invasiveness. J Biol Chem. 2008; 283:20770-8.
30. Fu Z, et al. Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol. 2008; 10:1076-82.
31. Laoukili J, et al. FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol. 2005; 7:126-36.
32. Wonsey D.R, Follettie M.T. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 2005; 65:5181-9.
33. Delahaye-Sourdeix M, et al. The 12p13.33/RAD52 Locus and Genetic Susceptibility to Squamous Cell Cancers of Upper Aerodigestive Tract. PLoS One. 2015; 10:e0117639.
34. Green M.R, et al. Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin's lymphoma. Genes Chromosomes Cancer. 2011; 50:313-26.
35. Gao J, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013; 6:pl1.
36. Cerami E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2:401-4.
37. Woloszynska-Read A, et al. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun. 2007; 7:21.
38. Woloszynska-Read A, et al. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage. Clin Cancer Res. 2011; 17:2170-80.
39. Domcke S, et al. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013; 4:2126.
40. McCloskey C.W, et al. A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population. Front Oncol. 2014; 4:53.
41. Garson K, et al. Technical challenges and limitations of current mouse models of ovarian cancer. J Ovarian Res. 2012; 5:39.
42. Clark-Knowles K.V, et al. Conditional inactivation of Brca1, and Rb in mouse ovaries results in the development of leiomyosarcomas. PLoS One. 2009; 4:p53. p. e8534.
43. Li N.F, et al. Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression. Cell Prolif. 2007; 40:780-94.
44. Leung T.W, et al. Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett. 2001; 507:59-66.
45. Wang Z, et al. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. Cancer Res. 2007; 67:8293-300.
46. Chan D.W, et al. Over-expression of FOXM1 transcription factor is associated with cervical cancer progression and pathogenesis. J Pathol. 2008; 215:245-52.
47. Zhang X, et al. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells. Oncotarget. 2014; 5:11365-80.
48. Harbour J.W, Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 2000; 14:2393-409.
49. Lam A.K, et al. FOXM1b, which is present at elevated levels in cancer cells, has a greater transforming potential than FOXM1c. Front Oncol. 2013; 3:11.
50. Ma R.Y, et al. Raf/MEK/MAPK signaling stimulates the nuclear translocation and transactivating activity of FOXM1c. J Cell Sci. 2005; 118:795-806.
51. Barrett C.L, et al. Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy. Proc Natl Acad Sci U S A. 2015; 112:E3050-7.
52. Chiu W.T, et al. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells. Oncotarget. 2015; 6:2349-65.
53. Zhao F, et al. Overexpression of Forkhead Box Protein M1 (FOXM1) in Ovarian Cancer Correlates with Poor Patient Survival and Contributes to Paclitaxel Resistance. PLoS One. 2014; 9:e113478.
54. Zhou J, et al. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLoS One. 2014; 9:e96989.
55. Wen N, et al. Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer. J Transl Med. 2014; 12:134.
56. Teh M.T, et al. Upregulation of FOXM1 induces genomic instability in human epidermal keratinocytes. Mol Cancer. 2010; 9:45.
57. Carter S.L, et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet. 2006; 38:1043-8.
58. Hanel W, Moll U.M. Moll, Links between mutant p53 and genomic instability. J Cell Biochem. 2012; 113:433-9.
59. Wang M, Gartel A.L. Micelle-encapsulated thiostrepton as an effective nanomedicine for inhibiting tumor growth and for suppressing FOXM1 in human xenografts. Mol Cancer Ther. 2011; 10:2287-97.
60. Radhakrishnan S.K, et al. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 2006; 66:9731-5.
61. Gormally M.V, et al. Suppression of the FOXM1 transcriptional programme via novel small molecule inhibition. Nat Commun. 2014; 5:5165.
62. Kalinichenko V.V, Kalin T.V. Is there potential to target FOXM1 for 'undruggable' lung cancers?. Expert Opin Ther Targets. 2015 1-3.
63. Beroukhim R, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007; 104:20007-12.
64. Schneider C.A, Rasband W.S, Eliceiri K.W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012; 9:671-5.
65. Robinson J.T, et al. Integrative genomics viewer. Nat Biotechnol. 2011; 29:24-6.
66. Flesken-Nikitin A, et al. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res. 2003; 63:3459-63.
67. Link P.A, et al. Distinct roles for histone methyltransferases G9a and GLP in cancer germ-line antigen gene regulation in human cancer cells and murine embryonic stem cells. Mol Cancer Res. 2009; 7:851-62.